drug · protein
ZEPBOUND
Marketedupdated 5mo ago/ tur-ZEP-ə-tyde /
by $LLY ELI LILLY & Co🔗 ChEMBL
Approvedannual revenue · 2024–2024peak $4.9B
community read0 votes
🐶 often sniffed alongside
top 6Protein drug with a maximum clinical stage of Approval (across all indications), with 6 approved and 8 investigational indications.
indications
investigational
Obesity
targets
Glucagon-like peptide 1 receptorGastric inhibitory polypeptide receptor
all catalysts(24)
approval · 24
May 13, 2022
approval
$LLY1142.85-0.61%
MOUNJARO (TIRZEPATIDE) — FDA approval
ZEPBOUND
→
Jul 28, 2023
approval
$LLY1142.85-0.61%
MOUNJARO (TIRZEPATIDE) — FDA approval
ZEPBOUND
→
Jul 28, 2023
approval
$LLY1142.85-0.61%
MOUNJARO (TIRZEPATIDE) — FDA approval
ZEPBOUND
→
Nov 8, 2023
approval
$LLY1142.85-0.61%
ZEPBOUND (TIRZEPATIDE) — FDA approval
ZEPBOUND
→
Mar 28, 2024
approval
$LLY1142.85-0.61%
ZEPBOUND (TIRZEPATIDE) — FDA approval
ZEPBOUND
→
Oct 18, 2024
approval
$LLY1142.85-0.61%
ZEPBOUND (TIRZEPATIDE) — FDA approval
ZEPBOUND
→
Oct 18, 2024
approval
$LLY1142.85-0.61%
ZEPBOUND (TIRZEPATIDE) — FDA approval
ZEPBOUND
→
Oct 18, 2024
approval
$LLY1142.85-0.61%
ZEPBOUND (TIRZEPATIDE) — FDA approval
ZEPBOUND
→
Oct 18, 2024
approval
$LLY1142.85-0.61%
ZEPBOUND (TIRZEPATIDE) — FDA approval
ZEPBOUND
→
Oct 18, 2024
approval
$LLY1142.85-0.61%
ZEPBOUND (TIRZEPATIDE) — FDA approval
ZEPBOUND
→
Nov 1, 2024
approval
$LLY1142.85-0.61%
MOUNJARO (TIRZEPATIDE) — FDA approval
ZEPBOUND
→
Nov 1, 2024
approval
$LLY1142.85-0.61%
MOUNJARO (TIRZEPATIDE) — FDA approval
ZEPBOUND
→
Nov 1, 2024
approval
$LLY1142.85-0.61%
MOUNJARO (TIRZEPATIDE) — FDA approval
ZEPBOUND
→
Dec 20, 2024
approval
$LLY1142.85-0.61%
ZEPBOUND (TIRZEPATIDE) — FDA approval
ZEPBOUND
→
Feb 7, 2025
approval
$LLY1142.85-0.61%
ZEPBOUND (TIRZEPATIDE) — FDA approval
ZEPBOUND
→
May 28, 2025
approval
$LLY1142.85-0.61%
MOUNJARO (TIRZEPATIDE) — FDA approval
ZEPBOUND
→
Sep 25, 2025
approval
$LLY1142.85-0.61%
ZEPBOUND (TIRZEPATIDE) — FDA approval
ZEPBOUND
→
Sep 25, 2025
approval
$LLY1142.85-0.61%
MOUNJARO (TIRZEPATIDE) — FDA approval
ZEPBOUND
→
Dec 19, 2025
approval
$LLY1142.85-0.61%
MOUNJARO (TIRZEPATIDE) — FDA approval
ZEPBOUND
→
Jan 7, 2026
approval
$LLY1142.85-0.61%
MOUNJARO (TIRZEPATIDE) — FDA approval
ZEPBOUND
→
Jan 7, 2026
approval
$LLY1142.85-0.61%
ZEPBOUND (TIRZEPATIDE) — FDA approval
ZEPBOUND
→
Jan 20, 2026
approval
$LLY1142.85-0.61%
MOUNJARO (TIRZEPATIDE) — FDA approval
ZEPBOUND
→
Jan 20, 2026
approval
$LLY1142.85-0.61%
ZEPBOUND (TIRZEPATIDE) — FDA approval
ZEPBOUND
→
Feb 25, 2026
approval
$LLY1142.85-0.61%
ZEPBOUND (TIRZEPATIDE) — FDA approval
ZEPBOUND
→
Trials studying ZEPBOUND
- phase3Efficacy, Safety, and Pharmacokinetics of Tirzepatide (LY3298176) Once Weekly Versus Placebo in Pediatric Participants 6 to Less Than 12 Years of Age Who Have Obesity (ADVANCE-SURMOUNT-KIDS)
- phase2Efficacy and Safety of Tirzepatide Versus Placebo or Lisdexamfetamine Dimesylate for Binge-Eating Disorder
- phase3A Study of Tirzepatide in Adolescents With Obesity and Weight-Related Comorbidities (SURMOUNT-ADOLESCENTS-2)
- phase3A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor
- phase4Bariatric Surgery vs. Semaglutide vs. Tirzepatide
- phase2A Study of SYH2069 Injection in Participants With T2DM Not Controlled With Diet/Exercise Alone or Metformin
- phase3Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight
- phase2A Study to Evaluate ALN-2232 in Participants With Obesity
Patent cliff
source: FDA Orange Bookfirst barrier falls
Nov 8, 2026
34 days
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (216)
- Dec 30, 2041method-of-use (U-4193)US 12295987
- Dec 30, 2041method-of-use (U-4192)US 12295987
- Dec 30, 2041method-of-use (U-4192)US 12295987
- Dec 30, 2041method-of-use (U-4193)US 12295987
- Dec 30, 2041method-of-use (U-4192)US 12295987
- Dec 30, 2041method-of-use (U-4192)US 12295987
- Dec 30, 2041method-of-use (U-4192)US 12295987
- Dec 30, 2041method-of-use (U-4192)US 12295987
- Dec 30, 2041method-of-use (U-4192)US 12295987
- Dec 30, 2041method-of-use (U-4192)US 12295987
- Dec 30, 2041method-of-use (U-4192)US 12295987
- Dec 30, 2041method-of-use (U-4192)US 12295987
- Dec 30, 2041method-of-use (U-4192)US 12295987
- Dec 30, 2041method-of-use (U-4192)US 12295987
- Dec 30, 2041method-of-use (U-4193)US 12295987
- Dec 30, 2041method-of-use (U-4192)US 12295987
- Dec 30, 2041method-of-use (U-4193)US 12295987
- Dec 30, 2041method-of-use (U-4192)US 12295987
- Dec 30, 2041method-of-use (U-4192)US 12295987
- Dec 30, 2041method-of-use (U-4192)US 12295987
- Dec 30, 2041method-of-use (U-4192)US 12295987
- Dec 30, 2041method-of-use (U-4193)US 12295987
- Dec 30, 2041method-of-use (U-4193)US 12295987
- Dec 30, 2041method-of-use (U-4193)US 12295987
- Jul 22, 2039method-of-use (U-4409)US 12343382
- Jul 22, 2039method-of-use (U-4232)US 12343382
- Jul 22, 2039method-of-use (U-4232)US 12343382
- Jul 22, 2039method-of-use (U-4232)US 12343382
- Jul 22, 2039method-of-use (U-4232)US 12343382
- Jul 22, 2039method-of-use (U-4228)US 12343382
- Jul 22, 2039method-of-use (U-4227)US 12343382
- Jul 22, 2039method-of-use (U-4231)US 12343382
- Jul 22, 2039method-of-use (U-4230)US 12343382
- Jul 22, 2039method-of-use (U-4230)US 12343382
- Jul 22, 2039method-of-use (U-4230)US 12343382
- Jul 22, 2039method-of-use (U-4230)US 12343382
- Jul 22, 2039method-of-use (U-4230)US 12343382
- Jul 22, 2039method-of-use (U-4229)US 12343382
- Jul 22, 2039method-of-use (U-4230)US 12343382
- Jul 22, 2039method-of-use (U-4230)US 12343382
- Jul 22, 2039method-of-use (U-4410)US 12343382
- Jul 22, 2039method-of-use (U-4410)US 12343382
- Jul 22, 2039method-of-use (U-4410)US 12343382
- Jul 22, 2039method-of-use (U-4410)US 12343382
- Jul 22, 2039method-of-use (U-4409)US 12343382
- Jul 22, 2039method-of-use (U-4409)US 12343382
- Jul 22, 2039method-of-use (U-4409)US 12343382
- Jul 22, 2039method-of-use (U-4409)US 12343382
- Jul 22, 2039method-of-use (U-4409)US 12343382
- Jul 22, 2039method-of-use (U-4400)US 12343382
- Jul 22, 2039method-of-use (U-4401)US 12343382
- Jul 22, 2039method-of-use (U-4400)US 12343382
- Jul 22, 2039method-of-use (U-4400)US 12343382
- Jul 22, 2039method-of-use (U-4409)US 12343382
- Jul 22, 2039method-of-use (U-4409)US 12343382
- Jul 22, 2039method-of-use (U-4410)US 12343382
- Jul 22, 2039method-of-use (U-4410)US 12343382
- Jul 22, 2039method-of-use (U-4410)US 12343382
- Jul 22, 2039method-of-use (U-4409)US 12343382
- Jul 22, 2039method-of-use (U-4410)US 12343382
- Jul 22, 2039method-of-use (U-4410)US 12343382
- Jul 22, 2039method-of-use (U-4410)US 12343382
- Jul 22, 2039method-of-use (U-4410)US 12343382
- Jul 22, 2039method-of-use (U-4409)US 12343382
- Jul 22, 2039method-of-use (U-4410)US 12343382
- Jul 22, 2039method-of-use (U-4400)US 12343382
- Jul 22, 2039method-of-use (U-4400)US 12343382
- Jul 22, 2039method-of-use (U-4232)US 12343382
- Jul 22, 2039method-of-use (U-4230)US 12343382
- Jul 22, 2039method-of-use (U-4400)US 12343382
- Jul 22, 2039method-of-use (U-4400)US 12343382
- Jul 22, 2039method-of-use (U-4230)US 12343382
- Jul 22, 2039method-of-use (U-4308)US 12453758
- Jul 22, 2039method-of-use (U-4308)US 12453758
- Jul 22, 2039method-of-use (U-4309)US 12453758
- Jul 22, 2039method-of-use (U-4311)US 12453758
- Jul 22, 2039method-of-use (U-4308)US 12453758
- Jul 22, 2039method-of-use (U-4308)US 12453758
- Jul 22, 2039method-of-use (U-4308)US 12453758
- Jul 22, 2039method-of-use (U-4308)US 12453758
- Jul 22, 2039method-of-use (U-4309)US 12453758
- Jul 22, 2039method-of-use (U-4308)US 12453758
- Jul 22, 2039method-of-use (U-4308)US 12453758
- Jul 22, 2039method-of-use (U-4311)US 12453758
- Jul 22, 2039method-of-use (U-4311)US 12453758
- Jul 22, 2039method-of-use (U-4311)US 12453758
- Jul 22, 2039method-of-use (U-4311)US 12453758
- Jul 22, 2039method-of-use (U-4311)US 12453758
- Jul 22, 2039method-of-use (U-4311)US 12453758
- Jul 22, 2039method-of-use (U-4311)US 12453758
- Jul 22, 2039method-of-use (U-4311)US 12453758
- Jul 22, 2039method-of-use (U-4308)US 12453758
- Jul 22, 2039method-of-use (U-4308)US 12453758
- Jul 22, 2039method-of-use (U-4308)US 12453758
- Jul 22, 2039method-of-use (U-4308)US 12453758
- Jul 22, 2039method-of-use (U-4311)US 12453758
- Jun 14, 2039compositionUS 11357820
- Jun 14, 2039compositionUS 11357820
- Jun 14, 2039formulationUS 11357820
- Jun 14, 2039formulationUS 11357820
- Jun 14, 2039formulationUS 11357820
- Jun 14, 2039formulationUS 11357820
- Jun 14, 2039formulationUS 11357820
- Jun 14, 2039compositionUS 11357820
- Jun 14, 2039compositionUS 11357820
- Jun 14, 2039formulationUS 11357820
- Jun 14, 2039formulationUS 11357820
- Jun 14, 2039formulationUS 11357820
- Jun 14, 2039compositionUS 11357820
- Jun 14, 2039formulationUS 11357820
- Jun 14, 2039formulationUS 11357820
- Jun 14, 2039formulationUS 11357820
- Jun 14, 2039formulationUS 11357820
- Jun 14, 2039formulationUS 11357820
- Jun 14, 2039formulationUS 11357820
- Jun 14, 2039formulationUS 11357820
- Jun 14, 2039formulationUS 11357820
- Jun 14, 2039formulationUS 11357820
- Jun 14, 2039compositionUS 11357820
- Jun 14, 2039formulationUS 11357820
- Jun 14, 2039method-of-use (U-3855)US 11918623
- Jun 14, 2039method-of-use (U-3855)US 11918623
- Jun 14, 2039method-of-use (U-3855)US 11918623
- Jun 14, 2039method-of-use (U-3855)US 11918623
- Jun 14, 2039method-of-use (U-3855)US 11918623
- Jun 14, 2039method-of-use (U-3855)US 11918623
- Jun 14, 2039method-of-use (U-3855)US 11918623
- Jun 14, 2039method-of-use (U-3855)US 11918623
- Jun 14, 2039method-of-use (U-3855)US 11918623
- Jun 14, 2039method-of-use (U-3855)US 11918623
- Jun 14, 2039method-of-use (U-3855)US 11918623
- Jun 14, 2039method-of-use (U-3855)US 11918623
- Jun 14, 2039method-of-use (U-4377)US 12453755
- Jun 14, 2039method-of-use (U-4385)US 12453755
- Jun 14, 2039method-of-use (U-4386)US 12453755
- Jun 14, 2039method-of-use (U-4378)US 12453755
- Jun 14, 2039method-of-use (U-4386)US 12453755
- Jun 14, 2039method-of-use (U-4381)US 12453755
- Jun 14, 2039method-of-use (U-4380)US 12453755
- Jun 14, 2039method-of-use (U-4377)US 12453755
- Jun 14, 2039method-of-use (U-4378)US 12453755
- Jun 14, 2039method-of-use (U-4386)US 12453755
- Jun 14, 2039method-of-use (U-4376)US 12453755
- Jun 14, 2039method-of-use (U-4383)US 12453755
- Jun 14, 2039formulationUS 12453756
- Jun 14, 2039formulationUS 12453756
- Jun 14, 2039formulationUS 12453756
- Jun 14, 2039formulationUS 12453756
- Jun 14, 2039formulationUS 12453756
- Jun 14, 2039formulationUS 12453756
- Jun 14, 2039formulationUS 12453756
- Jun 14, 2039formulationUS 12453756
- Jun 14, 2039formulationUS 12453756
- Jun 14, 2039formulationUS 12453756
- Jun 14, 2039formulationUS 12453756
- Jun 14, 2039formulationUS 12453756
- Jun 14, 2039formulationUS 12453756
- Jun 14, 2039formulationUS 12453756
- Jun 14, 2039formulationUS 12453756
- Jun 14, 2039formulationUS 12453756
- Jun 14, 2039formulationUS 12453756
- Jun 14, 2039formulationUS 12453756
- Jun 14, 2039formulationUS 12453756
- Jun 14, 2039formulationUS 12453756
- Jun 14, 2039formulationUS 12453756
- Jun 14, 2039formulationUS 12453756
- Jun 14, 2039formulationUS 12453756
- Jun 14, 2039formulationUS 12453756
- Jan 5, 2036compositionUS 9474780
- Jan 5, 2036compositionUS 9474780
- Jan 5, 2036compositionUS 9474780
- Jan 5, 2036compositionUS 9474780
- Jan 5, 2036compositionUS 9474780
- Jan 5, 2036compositionUS 9474780
- Jan 5, 2036compositionUS 9474780
- Jan 5, 2036compositionUS 9474780
- Jan 5, 2036compositionUS 9474780
- Jan 5, 2036compositionUS 9474780
- Jan 5, 2036compositionUS 9474780
- Jan 5, 2036compositionUS 9474780
- Jan 5, 2036compositionUS 9474780
- Jan 5, 2036compositionUS 9474780
- Jan 5, 2036compositionUS 9474780
- Jan 5, 2036compositionUS 9474780
- Jan 5, 2036compositionUS 9474780
- Jan 5, 2036compositionUS 9474780
- Jan 5, 2036compositionUS 9474780
- Jan 5, 2036compositionUS 9474780
- Jan 5, 2036compositionUS 9474780
- Jan 5, 2036compositionUS 9474780
- Jan 5, 2036compositionUS 9474780
- Jan 5, 2036compositionUS 9474780
- Jan 5, 2036compositionUS 9474780
- Jan 5, 2036compositionUS 9474780
- Jan 5, 2036compositionUS 9474780
- Jan 5, 2036compositionUS 9474780
- Jan 5, 2036compositionUS 9474780
- Jan 5, 2036compositionUS 9474780
- Jan 5, 2036compositionUS 9474780
- Jan 5, 2036compositionUS 9474780
- Jan 5, 2036compositionUS 9474780
- Jan 5, 2036compositionUS 9474780
- Jan 5, 2036compositionUS 9474780
- Jan 5, 2036compositionUS 9474780
- Jan 5, 2036compositionUS 9474780
- Jan 5, 2036compositionUS 9474780
- Jan 5, 2036compositionUS 9474780
- Jan 5, 2036compositionUS 9474780
- Jan 5, 2036compositionUS 9474780
- Jan 5, 2036compositionUS 9474780
- Jan 5, 2036compositionUS 9474780
- Jan 5, 2036compositionUS 9474780
- Jan 5, 2036compositionUS 9474780
- Jan 5, 2036compositionUS 9474780
- Jan 5, 2036compositionUS 9474780
- Jan 5, 2036compositionUS 9474780
FDA exclusivities (62)
- Dec 19, 2028NPPNew Product (3y)2.2y
- Dec 19, 2028NPPNew Product (3y)2.2y
- Dec 19, 2028NPPNew Product (3y)2.2y
- Dec 19, 2028NPPNew Product (3y)2.2y
- Dec 19, 2028NPPNew Product (3y)2.2y
- Dec 19, 2028NPPNew Product (3y)2.2y
- Dec 19, 2028NPPNew Product (3y)2.2y
- Dec 19, 2028NPPNew Product (3y)2.2y
- Dec 20, 2027I-958Indication (3y)1.2y
- Dec 20, 2027I-958Indication (3y)1.2y
- Dec 20, 2027I-958Indication (3y)1.2y
- Dec 20, 2027I-958Indication (3y)1.2y
- Dec 20, 2027I-958Indication (3y)1.2y
- Dec 20, 2027I-958Indication (3y)1.2y
- Dec 20, 2027I-958Indication (3y)1.2y
- Dec 20, 2027I-958Indication (3y)1.2y
- Dec 20, 2027I-958Indication (3y)1.2y
- Dec 20, 2027I-958Indication (3y)1.2y
- Dec 20, 2027I-958Indication (3y)1.2y
- Dec 20, 2027I-958Indication (3y)1.2y
- Oct 18, 2027M-82Method (3y)1.0y
- Oct 18, 2027M-82Method (3y)1.0y
- Oct 18, 2027M-82Method (3y)1.0y
- Oct 18, 2027M-82Method (3y)1.0y
- Oct 18, 2027M-82Method (3y)1.0y
- Oct 18, 2027M-82Method (3y)1.0y
- Oct 18, 2027M-82Method (3y)1.0y
- Oct 18, 2027M-82Method (3y)1.0y
- Oct 18, 2027M-82Method (3y)1.0y
- Oct 18, 2027M-82Method (3y)1.0y
- Oct 18, 2027M-82Method (3y)1.0y
- Oct 18, 2027M-82Method (3y)1.0y
- May 13, 2027NCENew Chemical Entity (5y)220d
- May 13, 2027NCENew Chemical Entity (5y)220d
- May 13, 2027NCENew Chemical Entity (5y)220d
- May 13, 2027NCENew Chemical Entity (5y)220d
- May 13, 2027NCENew Chemical Entity (5y)220d
- May 13, 2027NCENew Chemical Entity (5y)220d
- May 13, 2027NCENew Chemical Entity (5y)220d
- May 13, 2027NCENew Chemical Entity (5y)220d
- May 13, 2027NCENew Chemical Entity (5y)220d
- May 13, 2027NCENew Chemical Entity (5y)220d
- May 13, 2027NCENew Chemical Entity (5y)220d
- May 13, 2027NCENew Chemical Entity (5y)220d
- May 13, 2027NCENew Chemical Entity (5y)220d
- May 13, 2027NCENew Chemical Entity (5y)220d
- May 13, 2027NCENew Chemical Entity (5y)220d
- May 13, 2027NCENew Chemical Entity (5y)220d
- May 13, 2027NCENew Chemical Entity (5y)220d
- May 13, 2027NCENew Chemical Entity (5y)220d
- May 13, 2027NCENew Chemical Entity (5y)220d
- May 13, 2027NCENew Chemical Entity (5y)220d
- May 13, 2027NCENew Chemical Entity (5y)220d
- May 13, 2027NCENew Chemical Entity (5y)220d
- May 13, 2027NCENew Chemical Entity (5y)220d
- May 13, 2027NCENew Chemical Entity (5y)220d
- Nov 8, 2026NPNP34d
- Nov 8, 2026NPNP34d
- Nov 8, 2026NPNP34d
- Nov 8, 2026NPNP34d
- Nov 8, 2026NPNP34d
- Nov 8, 2026NPNP34d
News(10)
- This week in charts: Kodiak’s big comeback and Hengrui’s dealmakingThe latest installment in BioPharma Dive’s data visualization series features a closer look at Kodiak’s stock performance and Hengrui's ties with U.S. and European drugmakers.biopharma_dive · 2d ago
- STAT+: Lilly bypasses Australian pharmacies with DTC modelEli Lilly is launching LillyDirect to deliver Mounjaro straight to Australian patients’ doors — and local doctors and pharmacists aren’t thrilled.stat · 2d ago
- Kailera, Hengrui’s GLP-1/GIP candidate delivers weight, menstrual benefits to women with PMOSKailera Therapeutics and Hengrui Pharma’s weekly injection showed benefits beyond weight loss in a mid-stage trial, leading to more regular menstrual cycles in patients with polyendocrine metabolic…biospace · 2d ago
- 3 takeaways from a European obesity scientific meetingEli Lilly impressed with its amylin-Zepbound combination data. Elsewhere, Novo demonstrated continued weight loss following a switch to oral and AbbVie and Boehringer gave glimpses into their conte…biopharma_dive · 3d ago
- Fresenius Kabi manufacturing plant hit with FDA warning letter after adverse eventsPatients had adverse events after receiving a Fresenius Kabi medicine that experienced manufacturing deviations.biospace · 3d ago
- STAT+: Pharmalittle: We’re reading about a plan to lower Medicare drug prices, a Lilly obesity drug, and moreA final Medicare rule aimed at lowering prices for doctor-administered drugs applies to only four companies and saves 96% less than the initial proposalstat · 3d ago
- Recon: Sanofi, Regeneron expand partnership after Dupixent success; Lilly amylin-Zepbound combo succeeds in mid-stage trialWelcome to Regulatory Reconnaissance, your regulatory news and intelligence briefing.raps · 4d ago
- Superior weight loss, blood sugar control propel Lilly’s amylin-GIP/GLP-1 combo into Phase 3EloraTZP—a combination of an amylin asset and Eli Lilly’s approved obesity drug Zepbound—made a clean sweep of the primary and secondary endpoints in a mid-stage trial of adults with obesity and ty…biospace · 4d ago
- #EASD26: Lilly's amylin-Zepbound combo posts best-ever weight loss in patients with obesity and diabetesMILAN — Forget Wegovy and Zepbound. Never mind CagriSema, and even retatrutide. The latest big name in obesity is eloraTZP. Data revealed Wednesday show that Lilly's amylin-incretin combination del…endpoints · 4d ago
- STAT+: Eli Lilly’s Zepbound combined with amylin drug led to significant weight loss in mid-stage trialAn investigational combination therapy from Eli Lilly led to significant weight loss in a mid-stage study, but high discontinuation rates raise questions about tolerability.stat · 4d ago
Data sources
last refreshed 3m ago
Found something off?
comments(0)
5-min edit window · permanent after that